96 results about "Treatment field" patented technology

The invention belongs to the field of lung medical data processing and radiotherapy, and discloses a respiratory feature extraction method for chest and abdomen body surface point cloud partitioning by considering a lung physiological structure. After the body surface point cloud image is differentiated, correlation coefficient calculation is carried out according to a lung lobe model reconstructed by a lung 4DCT image, a body surface area highly correlated with a lung lobe structure is selected to carry out motion information dimension reduction recombination, and finally body surface global features of breathing are represented in a three-dimensional vector form. Compared with the prior art, the method has the advantages that the influence of the lung physiological structure on the lung tumor movement mode is creatively considered, meanwhile, the advantages of being noninvasive and free of extra dosage are kept, a new thought can be provided for development of the radiotherapy image guide technology, and further research in the field of thoracic and abdominal activity tumor radiotherapy is facilitated.

The invention discloses a CAR-T treatment response intelligent prediction system based on medical images, and relates to the field of medical image analysis and tumor immunotherapy, and the system comprises a data integration module, a multi-modal feature extraction module, a prediction model construction module, a model optimization module, a clinical analysis module and an adverse reaction risk early warning module. The system integrates PET-CT, MRI, ultrasound and other multi-mode medical image data, and extracts the form, texture and metabolic characteristics of the tumor; constructing a treatment response prediction model by adopting a three-dimensional convolutional neural network; innovatively applying a differential geometry theory, constructing a medical image manifold structure and generating a tumor adversarial sample maintaining topological characteristics, and executing an adaptive optimization strategy by using a Riemannian metric space; accurate prediction of CAR-T treatment response of a lymphoma patient is realized, and adverse reaction risk early warning is carried out through brain and visceral organ image analysis.

The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), and therapy. More specifically, the present disclosure relates to novel compositions useful in imaging and treatment of conditions such as prostate cancer, somatostatin receptor-expressing tumors, like neuroendocrine tumor, epithelial tumors, as well as to methods wherein such compositions are prepared.

The invention discloses a symmetric azaindole-heptamethine cyanine J-aggregate as well as a preparation method and application thereof, and aims to solve the problems of short absorption wavelength, poor stability and the like in the prior art. The cyanine J-aggregate has the maximum absorption wavelength as long as 1035 nm, is located in an NIR-II region and has excellent photo-thermal performance and stability, and the photo-thermal stability is improved by nearly 68% compared with that of an existing J-aggregate. The preparation method comprises multiple steps of reaction, and finally self-assembly is carried out in a PBS solution to form the J-aggregate. The cyanine J-aggregate shows the capabilities of efficiently killing tumor cells and completely ablating tumors in vivo in tumor photothermal therapy, is good in biocompatibility, expands the application scene of diagnosis and treatment integration, and has a wide prospect in the field of tumor photothermal therapy.

A multimodal deep learning framework which is used to determine the likelihood of a particular treatment method effectively treating a patient with ovarian / kidney cancer with the goal of increasing patient survival. The framework takes into account not only large histopathology images (whole slide images), but also clinical variables to increase the scope of the data. The results demonstrate that the proposed models achieve high prediction accuracy and interpretability and can also be transferred to other cancer datasets without significant loss of performance. One of the key innovations here is the combination of pathology and clinical variables in a deep learning model to provide recommendations in therapy areas with limited information.

A transducer device for delivering a tumor treatment field to a subject's body, the transducer device comprising: an electrode array configured to be positioned over the subject's body with a front face of the array facing the subject's body, the array comprising electrode elements positioned in existing electrode locations arranged about a centroid of the array; a layer of anisotropic material electrically coupled to the electrode array and located on an anterior side of the front face of the array; and at least one void space in the electrode array capable of enclosing at least a portion of an area footprint equivalent to an area footprint of the at least one existing electrode location and capable of being superimposed on at least a portion of the at least one existing electrode location by rotating the array about the centroid.

The present invention discloses a beta-ray therapy device and a method for using the same, which belongs to the field of nuclear medicine external radiation therapy. The device includes a therapy device body and a conformal structure. The therapy device body includes a beta-ray source and a beta-ray shielding structure. The beta-ray shielding structure has a mounting cavity and a window communicating with the mounting cavity. The beta-ray source is installed in the mounting cavity. The conformal structure includes a conformal frame and a plurality of conformal pieces. A transmission area is opened in the center of the conformal frame. The conformal pieces are installed on the conformal frame and are movable toward or away from the transmission area. By adjusting the position of the conformal piece, a conformal area surrounding a treatment target area is formed within the transmission area. The beta-ray source transmits beta-rays through the window toward the conformal area. The present invention can form conformal areas of different shapes according to different shapes of treatment target areas. Then, the beta-rays emitted by the beta-ray source transmit through the conformal area to irradiate the treatment target area, thereby allowing the same therapy device to treat treatment target areas of different shapes, thereby achieving versatility and adjustability.

1. A transducer device for delivering a tumor treatment field to a body of a subject, the transducer device comprising: an array of electrodes configured to be placed on a body of a subject with a front surface of the array facing the body of the subject, the array including electrode elements positioned at existing electrode locations positioned about a center of gravity of the array; an anisotropic material layer electrically coupled to the array of electrodes and positioned in front of the front surface of the array; and at least one void space within the array of electrodes capable of encompassing an areal footprint equal to at least a portion of the areal footprint of at least one existing electrode location and superimposable onto at least a portion of at least one existing electrode location by rotation of the array about the center of gravity.

Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells including an alternating polarity (AP) magnetic field generator and one or more AP electromagnetic coil adapted to be coupled to at least a portion of a patient's body, and a controller to control the AP magnetic field generator and at least one AP electromagnetic coil and cause the field generator and coil to apply AP magnetic field having a frequency of 0.5-500 KHz and a field strength of 0.5-5 mT to the at least a portion of the patient's body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer therapy such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, an angiogenesis inhibitor drug, or tumor treatment field therapy.

Methods and systems for positioning and positioning a patient for irradiation therapy without fiducial markers. Platform settings including parameters of the patient support platform are obtained. Platform position data is obtained in which a patient is placed on a platform for imaging without fiducial markers, the platform position data including 3D coordinates of the platform relative to an imager coordinate system calibrated to a predefined fixed set of initialized coordinates in a treatment room. Target tissue is imaged with the patient on the platform. A treatment plan is generated based on the target tissue imaging. The treatment plan comprises a treatment radiation field of a treatment angle, and the treatment angle comprises a platform positioning parameter. When treatment is initiated, the patient is placed on the platform without fiducial markers according to the platform settings. In accordance with the treatment plan, the platform position data, and a coordinate system transformation of the imager coordinate system to the treatment room coordinate system, the platform is adjusted to position the patient at the placement position in the treatment room such that the target tissue is positioned at the isocenter of the treatment room.

1. A transducer device for delivering a tumor treatment field to a subject's body, comprising: an electrode array configured to be positioned across the subject's body with a face of the array facing the subject's body, the array including electrode elements positioned in substantially symmetrical positions centered about a center of gravity of the array; a void space located between at least one pair of adjacent electrodes of the array; and a polymeric material layer overlying the electrode array and located on a side of the array facing away from the subject's body.

The invention discloses a near-infrared photosensitizer for specifically recognizing fibroblast activation protease (FAP-alpha) as well as a preparation method and application of the near-infrared photosensitizer. A cyanine derivative is used as a fluorescent parent nucleus (ICyOH) of the photosensitizer, the fluorescence of the photosensitizer can be almost completely masked by modifying the photosensitizer, and after the photosensitizer reacts with FAP-alpha for 60 minutes, the fluorescence intensity is rapidly enhanced, so that high sensitivity, good selectivity and anti-interference performance are shown. The ZGP-LL-ICy is a photosensitizer with a cyanine structure, FAP-alpha fluorescence enhancement and high selectivity to FAP-alpha, the reagent shows high selective response to FAP-alpha enzyme, active ICyOH molecules with near-infrared fluorescence are released under the action of enzymolysis, and tumor fluorescence imaging of deep tissue penetration is achieved. Meanwhile, the activated ICyOH can generate cytotoxic active oxygen under the illumination condition, and photodynamic therapy on pancreatic cancer is achieved. The reagent has the advantages of low background fluorescence, deep tissue penetration, diagnosis and treatment integration and the like, and has important application value in the fields of early diagnosis and precise treatment of pancreatic cancer.

The application discloses a lenvatinib-polyethylene glycol coupling compound and a preparation method and application thereof. The lenvatinib-polyethylene glycol coupling compound has a structure as shown in the formula (I): in the formula (I), n is greater than or equal to 2. The application further provides a nano preparation containing vinpocetine and the lenvatinib-polyethylene glycol coupling compound and used for manufacturing drugs, which can be applied to tumor treatment, effectively improves the limitation of a single drug treatment method on tumor inhibition, and shows a positive application potential in the tumor treatment field.

1. The name of the design product: radiological imaging device. 2. The use of the design product: the design product is used in the field of medical radiation treatment to display the image of medical radiation. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1. 5. The design claimed contains color.

A therapy assembly can have an inner layer having an inner surface and an outer surface and defining a plurality of openings extending therethrough. The therapy assembly can also include a plurality of plates, each plate at least partially received within a respective opening of the plurality of openings of the inner layer. The therapy assembly can also include therapy circuitry including a cable having a plurality of electrical leads and a plurality of lead ends, each electrical lead electrically connected to a respective lead end of the plurality of lead ends. A cover layer can be attached to the outer surface of the inner layer and cover the plurality of lead ends of the cable. The plurality of lead ends can be in contact with a respective plate of the plurality of plates to define a plurality of electrodes.

The application belongs to the field of fluorescent probes, and particularly relates to a tumor-targeting photothermal reagent based on fluoro-rhodamine, and a preparation method and application thereof. To solve the problems that most of existing photothermal reagents have difficulty in post-modification due to complex synthesis, poor biological compatibility due to large molecular weight, and lack of tumor targeting of these molecules, and generally need to be made into nanoparticles to enrich to the tumor site by EPR effect, the application develops a tumor-targeting photothermal reagent Tag-880-NHS based on fluoro-rhodamine, which has the characteristics of simple synthesis, good water solubility, good light stability, high photothermal conversion efficiency, and an absorption wavelength located in the NIR region, and can be used for labeling a specific targeting epidermal growth factor monoclonal antibody-panitumumab, and can be used in the fields of tumor imaging and treatment, and has important application value.

The invention belongs to the technical field of medical diagnosis, and particularly relates to a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscesses and interactive application. According to the invention, it is found that six indexes including serum uric acid (UA), thrombin time (TT), neutrophil absolute value (NEUT #), age (Age), fever (Fever) and erythrocyte sedimentation rate (ESR) are related to the type of the lumbar major muscle abscess, and a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscess and interactive application are invented. And a first visual and quantifiable column diagram (Nomogram) prediction model for differential diagnosis of lumbar major muscle abscess is provided for the field. The technical problem that an abstract mathematical prediction model is converted into a visual graphic diagnosis tool which is intuitive in form and convenient to operate is solved, so that the visual graphic diagnosis tool can be separated from dependence on specific computing equipment, and clinical medical staff can quickly and accurately apply the visual graphic diagnosis tool on a diagnosis and treatment site conveniently.

A method for assisting in transducer placement on a subject's body to apply a tumor treating field includes determining first image data based on one or more images associated with a portion of the subject's body, the first image data including one or more transducer placement locations; determining second image data based on the one or more images, the second image data including one or more recommended transducer placement locations; registering the second image data to the first image data; and generating composite data including the one or more transducer placement locations and the one or more recommended transducer array placement locations.

The application is suitable for the medical diagnosis and treatment field, and provides an auxiliary decision-making method and system applied to ultrasonic diagnosis and treatment, a medium and medical equipment.The method comprises the following steps: in response to a selection instruction of a user, a target logical decision workflow selected by the user is loaded; whether a standardized image acquisition workflow is pre-associated with a current decision node of the target logical decision workflow is judged; if yes, the image acquisition workflow associated with the current decision node is activated; a decision option selected by the user for a judgment question of the current decision node is received, and the current decision node, the decision option and an ultrasonic image associated with the decision option are data-associated to form structured decision evidence and are stored; according to a preset logical relationship of the decision option and the target logical decision workflow, a next decision node is determined and entered until a conclusion node is reached.The application solves the problems of insufficient quality, efficiency and reliability of the existing ultrasonic diagnosis and treatment.

The invention provides a bifunctional fusion protein radionuclide marker with a brand new structure model, which has higher labeling rate and radiochemical purity, keeps higher affinity and functional activity, and has proper molecular weight, strong tissue penetrability, good imaging effect, proper cycle half-life period and strong molecular stability. After a target carrier is radiolabeled, the target carrier still shows good affinity and is not affected, has good biological metabolic activity and clearance rate, has the effects of reducing radiation toxicity, kidney toxicity, blood toxicity and non-target organ toxicity, is well enriched in tumor cells, is beneficial to realizing diagnosis and accurate staging of tumor focuses, and can be used as a target carrier to improve the clinical application prospect. Precise radiotherapy of primary focuses and metastatic focuses is achieved, good safety and effectiveness potential are achieved, and good application prospects are achieved in the field of solid tumor treatment.

This document describes a system and method for administering TTFields. The system comprises an electric field generator that produces a signal with a frequency of 50 kHz to 1 MHz and is connected to an electrode. A pad, connected to the electrode, includes a continuous-phase solid material and a conductive gel. The continuous-phase solid material receives the signal from the electrode, has a surface in contact with the skin, and is made of a conductive material or has a conductive material adhered, absorbed, or adsorbed onto it. The surface in contact with the skin has cavities whose size and dimensions allow for the accommodation of a hair follicle. The conductive gel is adhered, absorbed, or adsorbed onto the surface in contact with the skin and is located within some of these cavities.

The present invention relates to a multileaf collimator and a radiotherapy machine comprising the same. A multilayer multileaf collimator (MLC) includes an outboard shielding member that spans or extends across a treatment field from a guide feature in a first leaf bank to a matching guide feature in an opposing second leaf bank. Unlike pairs of beam blocking leaves that extend to a central portion of the treatment field, each outboard shielding member extends across the treatment field from within an outer edge of one leaf bank to a corresponding outer edge of the opposing leaf bank.

The invention discloses an optimization algorithm for balancing the plan quality and irradiation efficiency of proton arc therapy, and belongs to the field of radiotherapy, and the optimization algorithm comprises the steps: S1, reading the image and structure data of a patient; s2, generating a beam spot position according to the patient image and the structure data; s3, setting clinical requirements, including target region prescription dose, organ-endangering dose limit value, weight of each objective function item and weight of constraint conditions; s4, a dose calculation engine is called, dose distribution under current beam parameters is calculated, and the beam parameters comprise an energy layer, a beam spot position and a beam spot weight; and S5, continuously updating beam parameters according to an objective function and constraints by adopting an optimization algorithm in combination with machine parameter limitation, and searching an optimal solution in a beam parameter space. An optimization algorithm is adopted, the dose and the irradiation efficiency are directly combined, the rack rotation speed, the energy layer switching and the beam spot scanning time are considered in the calculated irradiation time, the contradiction between the proton arc treatment plan quality and the irradiation efficiency is allowed to be directly optimized and processed, and a proper plan is selected according to the clinical background.

Methods and systems for radiation treatment planning use objective function formulations to evaluate a proposed (candidate) radiation treatment plan, to determine whether or not clinical goals that are specified for treatment of a patient are satisfied by the plan. Dose distributions for a region of a target volume are generated. A value of an objective function formulation is determined. The value of the objective function formulation is a function of difference between a value that is based on a dose distribution and a value for a range that is associated with the treatment field corresponding to the dose distribution. In this manner, the uniformity of doses of individual treatment fields can be controlled. The value of the objective function formulation can be used in a process for optimizing dose distributions in the radiation treatment plan.

The invention relates to an automatic treatment field segmentation method for controlling a treatment time in a plan. The method comprises defining a radiation field associated with an initially defined radiation process; automatically segmenting the radiation field into a plurality of N sub-fields based on a set of criteria, wherein N > 2 and n e N, said set of criteria comprising at least a time limit associated with a duration of the radiation process for at least one of the N sub-fields; and providing a radiation beam configuration to control a radiation device adapted to provide the radiation process associated with the segmented radiation field.